Repaglinide

This page contains recent news articles, when available, and an overview of Repaglinide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Repaglinide (when available)

Pharmacology and use:
Repaglinide is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations. For the treatment of Type II diabetes mellitus

Mechanism Of Action:
Repaglinide closes ATP-dependent potassium channels in the b-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the b-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.

News Articles on Repaglinide

Better weight control with metformin and insulin  -  ‎Nov 11, 2009‎
However, weight gain was less with metformin plus insulin than with repaglinide plus insulin (difference in mean body weight between treatments –2.51 kg). ... Endochrinology Update

FDA Safety Changes: DepoDur, Neoral, Lexiva  -  ‎Nov 4, 2009‎
Cyclosporine may increase the plasma concentrations of repaglinide and thereby increase the risk for hypoglycemia, the FDA warned. Repaglinide appears to be ... Medscape

Modern insulins drive up Novo Nordisk earnings  -  ‎Oct 29, 2009‎
Human insulins slipped 2% to 2.48 billion kroner and oral antidiabetic products, notably NovoNorm/Prandin (repaglinide), were down 3% to 650 million kroner. ... Pharma Times

Europe's CHMP Supports Approval of Five Generic Products  -  ‎Aug 13, 2009‎
Generic-drug maker Krka received positive opinions for its Enyglid (repaglinide) and Repaglinide Krka, which are versions of Novo Nordisk's Type 2 diabetes FDA news (subscription)

Novo earnings soar, FDA to report back on Victoza soon  -  ‎Aug 6, 2009‎
Oral antidiabetic products, notably NovoNorm/Prandin (repaglinide), were up 22% to 1.37 billion kroner. Among the major products in Novo's Pharma Times

노보 놀디스�?�, �?반기 매출 17%-수�?� 39% �?승  -  ‎Aug 7, 2009‎
...�?종 �?��?린 제품�?� Levemir(insuline detemir), NovoRapid(insulin aspart)가 31% 성장한 104억 �?�로네�?�고 경구 당뇨치료제 NovoNorm/Prandin(repaglinide)가 22% 메디포뉴스

Biotech/Pharma Docket  -  ‎Jun 23, 2009‎
6677358, covers a method for treating Type II diabetes using repaglinide in combination with metformin. In 2007, following the filing of the suit, Patent Docs

Benefit of glinides is not proven  -  ‎Jun 18, 2009‎
Although repaglinide has been approved for 10 years and nateglinide for 8 years in Germany, there have been no relevant trials to date of longer duration Genetic Engineering News (press release)

Initiation of insulin therapy in elderly patients taking oral ...  -  ‎Jun 22, 2009‎
1500 mg for tolbutamide, 375 mg for chlropropamide, 160 mg for glicalizide, 10 mg for glyburide, 4 mg for repaglinide and 2 mg for glimepiride. CMAJ

Diabetes drug used as diet pill  -  ‎Mar 4, 2009‎
According to pharma experts, diabetes medications like insulin, metformin, and repaglinide are being used by several people in the country for indications Daily News & Analysis

PrandiMet®, First Repaglinide and Metformin HCl Fixed Dose ...  -  04 Feb 2009
The combination of metformin and repaglinide has been shown to effectively reduce A1c levels. Although Prandin ® and metformin HCl have been used together Earthtimes (press release),

What's the evidence for meglitinides?  -  Jan 21, 2009
...[4] Three studies have shown that a meglitinide called repaglinide works about as well as drugs called sulphonylureas for controlling type 2 diabetes. guardian.co.uk,

Preoperative therapy for patients with resectable adenocarcinoma ...  -  Feb 3, 2009
He had diabetes diagnosed 2 years prior to his presentation and was taking repaglinide 0.5 mg daily. Physical examination was unremarkable except for American Journal of Hemotology and Oncology,

Novo Nordisk profits soar, driven by modern insulins  -  Jan 30, 2009
...an increase of 29%, while sales of oral antidiabetic products, notably NovoNorm/Prandin (repaglinide), were up 18% to 602 million kroner. Pharma Times,

Glucose Lowering to Control Macrovascular Disease in Type 2 Diabetes  -  Nov 4, 2008
Standard therapy and especially intensive treatment required the use of multiple agents, which included metformin, glimepiride, repaglinide, rosiglitazone, Journal of American Medical Association (subscription),

Novo Nordisk posts strong set of results and gets ready to spend  -  Oct 31, 2008
...an increase of 22%, while sales of oral antidiabetic products, notably NovoNorm/Prandin (repaglinide), were up 9% to 1.79 billion kroner. Pharma Times (registration),

Nearly Nine Out Of Ten Patients With Type 2 Diabetes Achieve QoF ...  -  Aug 31, 2008
Repaglinide has a distinct mode of action that helps control HbA1c by predominantly targeting post prandial glucose7. The new NICE guidance highlights the Medical News Today (press release),

奧�?�瘋比賽�?出門猛�?�猛�?�?心血糖值飆�?�  -  Aug 21, 2008
Meglitinide，如Repaglinide 中時電�?報,

Nearly Nine Out Of Ten Patients With Type 2 Diabetes Achieve QoF ...  -  Jul 20, 2008
Repaglinide has a distinct mode of action that helps control HbA1c by predominantly targeting post prandial glucose(7). The new NICE guidance highlights the Medical News Today (press release),

Novo Nordisk shares fall as investors wait for liraglitude news  -  Aug 8, 2008
Sales of oral antidiabetic products, notably NovoNorm/Prandin (repaglinide), were up 6% to 1.12 billion kroner. Among the major products in Novo's Pharma Times (subscription),

Sciele Pharma Inc. Q2 2008 Earnings Call Transcript  -  Jul 30, 2008
PrandinMet, which is a combination of repaglinide and metformin for the treatment of type II diabetes was approved by the FDA in June 2008. Seeking Alpha,

Sciele Pharma Inc. Q4 2007 Earnings Call Transcript  -  Mar 7, 2008
...we also strengthened our position in the diabetes market through an exclusive US marketing agreement with Novo Nordisk to market Prandin (repaglinide), Seeking Alpha,

Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year ...  -  Feb 27, 2008
...to market Prandin (repaglinide), and upon FDA approval, PrandiMet (combination of repaglinide and metformin) for the treatment of Type II diabetes. FOXBusiness

What You Should Know About Type 2 Medications  -  Feb 12, 2008
...and glinides like nateglinide and repaglinide); those that enhance insulin sensitivity (glitazones like pioglitazone (Actos) and rosiglitazone (Avandia) Diabetes Health (press release),

Brand Names/Synonyms:
Repaglinide is also known by the following brand names and/or synonyms:
AG-EE 388 ZW; AG-EE 623 ZW; Prandin; Repaglinida [Inn-Spanish]; Repaglinide; Repaglinide [Usan]; Repaglinidum [Inn-Latin]

Drug Category:
Repaglinide is categorized under the following by the FDA: Hypoglycemic Agents; Meglitinides; ATC:A10BX02

Dosage Forms:
TABLET

Absorption:
Rapid (bioavailability is 56%)

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
2-ethoxy-4-[[3-methyl-1-[2-(1-piperidyl)phenyl]-butyl]carbamoylmethyl]benzoicacid

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.